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ABSTRACT
A 63-year-old man was referred to our hospital
because of a dry cough. His chest roentgenogram
revealed ground-glass opacities and honeycomb for-
mations bilaterally in the lower lung fields. Pulmonary
function tests showed a depleted lung volume and
decreased arterial oxygen tension. He was clinically
diagnosed as having idiopathic interstitial pneumonia
(IIP). A β2-adrenoceptor agonist was administrated
because the patient’s symptoms improved after its
inhalation. Following treatment with an oral β2-
adrenoceptor agonist, the dry cough disappeared,
lung function tests remained unchanged and an
improvement in arterial oxygen tension was observed.
Although β2-adrenoceptor agonist therapy does not
improve disease activity or progression in patients with
IIP, its use may mitigate symptoms associated with the
disease.
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INTRODUCTION
A proliferation of extravascular and/or extrabronchial
parenchymal smooth muscle cells is one of the character-
istic histologic features of idiopathic interstitial pneu-
monia (IIP).1 β2-Adrenoceptor agonists have a preventive
effect on both the contraction of smooth muscles and
the proliferation of smooth muscle cells.2,3 We are
unaware of any studies describing the clinical course of
patients with IIP during long-term treatment with a β2-
adrenoceptor agonist. Herein, we describe a case of a
patient with IIP who underwent treatment with an oral 
β2-adrenoceptor agonist for 1 year. His clinical symptoms
disappeared, his respiratory function tests did not worsen
and his arterial oxygen tension improved following 
treatment.
CLINICAL SUMMARY
A 63-year-old man was admitted to our hospital to
undergo follow-up tests of an abnormal chest roentgeno-
gram and a severe dry cough. He had worked as a cattle
breeder for 48 years and, thus, frequently handled hay
feed for cattle. He was a life-long non-smoker. Chest
auscultation revealed fine crackles over the lower lung
fields bilaterally. His chest roentgenogram and chest
computed tomography (CT) scan (Fig. 1) revealed ground-
glass opacities and honeycomb formations throughout
the lower lung fields. Laboratory findings showed 
normal hematologic, hepatic and renal function and no
abnormalities in serum protein electrophoresis and
immunoglobulins. In particular, the patient’s serum IgE
concentration was normal. The serum Krebs von den
Lungen-6 (KL-6) concentration was 873 U/mL (normal
upper limit 500 U/mL). Autoimmune antibodies and pre-
cipitating antibodies to mold antigens were not found.
Pulmonary function tests revealed a reduced total lung
capacity (TLC; 3.77 L, 75% of predicted) but normal
carbon monoxide diffusing capacity (carbon monoxide
diffusing capacity adjusted for alveolar volume (perme-
ability index; DL/VA) 4.64 mL/min per mmHg per L;
101%). Arterial blood gas analysis during breathing of
room air in the sitting position showed the following: pH
7.418; PaO 2 78 mmHg; PaCO 2 46.4 mmHg; alveolar–
arterial oxygen tension difference (AaDO 2) 16.3 mmHg.
Broncho-alveolar lavage fluid (BALF) findings showed 
a slightly increased neutrophil ratio (5.4%) and an
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increased CD4/8 ratio (4.11). Microbiologic analyses of
BALF ruled out the possibility of infectious diseases.
Findings of transbronchial lung biopsy showed slight 
lymphocyte infiltration in the alveolar septa, thickened
alveolar walls, no foreign body depositions, no vasculitis
and no granulomas. Transbronchial bronchial biopsy
demonstrated an absence of eosinophil infiltration and
no goblet cell hyperplasias in the bronchial epithelium.
Bronchial hypersensitivity was examined using a method
developed by Takishima et al. (Astogragh™; Chest 
MI, Tokyo, Japan) involving continuous methacholine 
inhalation with simultaneous measurement of respiratory
resistance (Rrs; cm H2O/L per s). Baseline Rrs was
3.7 cm H2O/L per s and no bronchial hypersensitivity
was detected. Nevertheless, the patient’s dry cough
almost completely disappeared after inhalation of a 
β2-adrenoceptor agonist.
The patient was diagnosed as having IIP and under-
went treatment with an oral β2-adrenoceptor agonist
(salbutamol; 2 µg/kg) in order to relieve the dry 
cough. After a follow-up period of 1 year, his dry cough
had almost completely disappeared, TLC and DL/VA
values were essentially the same (3.89 L (77%) and
4.62 mL/min per mmHg per L (100%), respectively) and
the PaO 2 and AaDO 2 showed an improvement (95 and
4.1 mmHg, respectively). His serum KL-6 concentration
improved to 580 U/mL, but was still above the normal
upper limit.
Bronchial hypersensitivity test
To determine whether patients with IIP show bronchial
hypersensitivity, we examined seven male and three
female IIP patients in a study using the methacholine
inhalation method. All patients approved of the study
objective and all gave written informed consent to partic-
ipate. The patients were all non-smokers and none had 
a history of corticosteroid treatment. There is a strong
association between bronchial hyperresponsiveness and
smoking4 and, thus, to exclude the influence of smoking,
study participants were limited to non-smokers. The
methacholine inhalation method is described below.
Two-fold increasing concentrations of methacholine
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Fig. 1 Chest computed tomography scan. Note the ground-
glass opacities and honeycomb formations in the lower lung
fields bilaterally.
Fig. 2 Results of bronchial
hypersensitivity test by continuous
methacholine inhalation method.
Note that none of the patients
with idiopathic interstitial pneu-
monia showed bronchial hyper-
sensitivity. Total methacholine
concentration in 1 min inhalation
(mg/mL) is as follows: T1 =
0.049, T2 = 0.098, T3 =
0.195, T4 = 0.391, T5 = 0.781,
T6 = 1.56, T7 = 3.13, T8 =
6.25, T9 = 12.5 and T10 =
25.0. C, 0.9% NaCl inhalation;
T, methacholine inhalation.
chloride diluted in physiologic saline, from 0.049 to
25 mg/mL, were inhaled from Bird micronebulizers (Bird
Corp., Palm Springs, CA, USA) with an output of
0.15 mL/min. The particle size ranged from 0.5 to
4.0 mm. The Rrs was measured by 3 Hz forced-
oscillation method. After recording baseline Rrs (physio-
logic saline inhalation), methacholine was inhaled
sequentially at 1 min. intervals. Respiratory conductance
(Grs; the reciprocal of Rrs) was plotted and the cumula-
tive dose of methacholine that decreased Grs to 65% of
the baseline level was obtained as PD35Grs from each
dose–response curve. This parameter was measured in
terms of a unit defined as 1 min inhalation of metha-
choline. Mean (±SEM) baseline Rrs was 3.6±0.4 cm
H2O/L per s and none of the patients showed bronchial
hypersensitivity (Fig. 2).
DISCUSSION
Because no standard treatment has yet been established
for IIP, it is difficult for clinicians to select the appropriate
timing of treatment and therapeutic approach, especially
during the early stages of disease progression. In the
present case, after 1 year of treatment with a β2-
adrenoceptor agonist, the clinical symptoms disappeared,
the respiratory function tests were unchanged and an
improvement in arterial oxygen tension was observed.
However, we could not discontinue and restart β2-
adrenoceptor agonist treatment at the appropriate time
to clarify its effectiveness. Because the patient underwent
treatment for only 1 year, a longer observation period
and a control study with and without the administration of
a β2-adrenoceptor agonist is needed to clarify the effi-
cacy of this drug and its possible contribution to the
prognosis of patients with IIP. The present IIP patient was
believed to be in a stable condition based on the respira-
tory function tests and roentgenographic findings. None
of the clinical parameters improved completely in
response to treatment with the β2-adrenoceptor agonist.
Treatment with a β2-adrenoceptor agonist does improve
clinical symptoms in patients with IIP, but cannot be con-
cluded to have a positive impact on disease activity and
progression.
A diagnosis of chronic farmer’s lung disease was
attractive given that the patient had worked as a farmer
for 48 years. However, a negative precipitin reaction to
mold antigens and a lack of improvement in chest
roentgenogram findings, despite the fact that the patient
had been hospitalized for approximately 1 month and,
thus, not exposed to mold and hay antigens suggested
that this diagnosis was unlikely. An absence of eosino-
philia in the peripheral blood and BALF, a normal serum
IgE titer, no bronchial hypersensitivity to methacholine
and bronchial biopsy specimen findings rule out the 
possibility of complications by bronchial asthma or
eosinophilic pneumonia.
The fact that the patient’s cough, which was resistant to
antitussives and expectorants, was temporary relieved by
inhalation of a β2-adrenoceptor agonist at the time of the
methacholine challenge test prompted us to attempt
treatment with this drug. To ensure compliance, we chose
oral tablets instead of regular inhalation. Numerous
drugs have pharmacologic effects on smooth muscle
hyperplasia and hypertrophy.5,6 Because β2-adrenoceptor
agonists have an inhibitory effect on proliferation and a
relaxing effect on the tone of smooth muscles, their use
may be indicated in cases involving patients with IIP, given
that they may mitigate some of the symptoms. The 
frequency of bronchial hypersensitivity in patients with 
IIP remains unclear. We are unaware of any studies on the
relationship between IIP and bronchial hypersensitivity
and, thus, further clinical investigation should be 
considered.
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